Knight Therapeutics Inc. has had a mixed week in its stock performance, influenced by recent financial results and operational updates that have affected investor sentiment.
Knight Therapeutics Inc. (GUD.TO) closed at C$9.59 on Thursday, marking a slight increase of 0.10% for the day. However, the stock has seen a minor decline of 0.61% over the past week, reflecting a more cautious outlook from investors despite positive developments in the company’s financial health and operations.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$957.76M
P/E
65.0x
52W high
$10.17
52W low
$5.66
1W change
-0.61%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 14.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+14.6% Upside
Current Price
C$9.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.3%
Annualized
90-Day Vol
32.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.36 | C$9.27 – C$11.58 |
| 60 trading days | C$10.99 | C$9.39 – C$12.87 |
| 90 trading days | C$11.67 | C$9.62 – C$14.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should weigh the recent positive financial results and increased revenue guidance against the stock's performance and technical indicators. While the stock has shown a remarkable year-to-date increase, it's important to consider overall market conditions and company-specific news.
Knight Therapeutics Reports 34% Revenue Increase in Q2 2026
The company's revenues reached C$144.2 million, indicating strong growth but resulting in a net loss of C$0.03 per share.
Bull case
Knight Therapeutics reported a significant 34% increase in revenues year-over-year for Q2 2026, along with an improved net loss performance. The company has also raised its revenue guidance for the year, showing strong operational momentum and potential for growth.
Bear case
Despite the positive financial results, Knight's stock has seen a slight decline over the past week, with trading volume significantly below the 20-day average. This could signal a lack of strong buying interest or market concerns about the company's profitability, which is reflected in its low profit margin and high P/E ratio.
Price Action Overview
Advertisement
Knight Therapeutics Inc. (GUD.TO) closed at C$9.59, reflecting a slight increase of 0.10% for the day. Over the past week, the stock has experienced a minor decline of 0.61%. Year-to-date, the stock remains strong with a notable increase of 65.14%, indicating resilience and positive investor sentiment overall.
Recent Company News
Knight Therapeutics recently announced its Q2 2026 financial results, showcasing a revenue increase of 34% year-over-year, reaching C$144.2 million. Despite this growth, the company reported a net loss of C$0.03 per share, an improvement from a loss of C$0.13 per share in the previous year. Furthermore, the company raised its 2026 revenue guidance to a range of C$540 million to C$560 million, demonstrating confidence in its growth trajectory. Additionally, Knight repaid its US$100 million revolving credit facility, marking a significant milestone following its acquisition of Paladin.
Technical Picture
Knight Therapeutics is currently trading at C$9.59, slightly below its 50-day moving average of C$9.63, indicating a marginal bearish trend. The stock's 200-day moving average stands at C$7.48, a significant 28.1% above the current price, suggesting a longer-term bullish trend. The 52-week range for GUD.TO is C$5.66 to C$10.17, with the current price sitting at 87% of this range. The stock has a low beta of 0.05, indicating lower volatility compared to the market. Trading volume was reported at 35,908 shares, significantly below the 20-day average volume of 95,499 shares, which may reflect reduced trading interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
